Invivyd Inc (IVVD) Stock Price, Quote & News

Company Profile

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 819 0080

Website: www.invivyd.com

Address:

209 Church Street, New Haven, United States

Doom_Gloom_AR May. 12 at 11:45 PM

$IVVD still here

1 · Reply

trader2sde May. 11 at 11:40 PM

$IVVD https://nypost.com/2026/05/11/us-news/doj-weighing-new-criminal-case-against-dr-fauci-despite-bidens-autopen-pardon-and-statute-of-limitations/

0 · Reply

gb2017384 May. 11 at 3:32 PM

$IVVD ,IF THIS EVER GETS APPROVED,WHAT DOES EVERYONE THINK THE STOCK WILL PEAK AT THAT DAY ?,MY.GUESS WOULD BE BETWEEN $5 AND $7 A SHARE.

0 · Reply

trader2sde May. 11 at 12:32 PM

$IVVD news. !

0 · Reply

DARKP00L May. 11 at 11:20 AM

$IVVD 07:13 on May. 11 2026 Invivyd EVADE Trial Data Reveals Monoclonal Antibody VYD2311 Demonstrates Minimal Tolerability Issues Versus COVID mRNA Vaccination #tradeideas

0 · Reply

focafoca99 May. 11 at 11:18 AM

$IVVD rolled out a preprint comparing early tolerability of its low‑dose COVID monoclonal antibody to vaccine side effects.

0 · Reply

trader2sde May. 11 at 8:12 AM

$IVVD US infected people sent all to Nebraska facility by Federal gvt vs anti Trump Europe/WHO authorities freeing ALL european infected to their countries ???????????covid part 2 mail in ballot "against trump movement" world crisis repeat ????

0 · Reply

trader2sde May. 11 at 8:05 AM

$IVVD THIS IS SERIOUS. and major scandal in the making https://www.youtube.com/watch?v=j7fPU1Kp5mA

0 · Reply

trader2sde May. 11 at 1:13 AM

$IVVD why if everything if fine ?.... observe all info and think. it is that or sink the boat.

0 · Reply

trader2sde May. 10 at 9:07 PM

$IVVD mmhh.... in the meantime British Air force dropped soldiers on tiny island where an infected british passenger was landed... mmhh.. IF IVVD SAYS ANYTHING ABT MABS HANTA STOCK will double in a week...

0 · Reply

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

May 7, 2026, 7:01 AM EDT - 6 days ago

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

May 5, 2026, 7:01 AM EDT - 8 days ago

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-04-20T11:28:23.000Z - 23 days ago

Invivyd annouces Chairman Elia to speak at POLITICO Health Care Summit

Apr 20, 2026, 7:01 AM EDT - 23 days ago

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

2026-04-09T13:34:05.000Z - 4 weeks ago

Invivyd provides update on Phase 3 DECLARATION study of VYD2311

2026-04-09T13:33:36.000Z - 4 weeks ago

Invivyd announces discovery, advancement of measles antibody candidate VMS063

Apr 9, 2026, 8:30 AM EDT - 4 weeks ago

Invivyd Transcript: Study update

Apr 9, 2026, 7:01 AM EDT - 4 weeks ago

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Mar 30, 2026, 4:05 PM EDT - 6 weeks ago

Invivyd Announces Presentation at the World Vaccine Congress Washington

Mar 5, 2026, 8:30 AM EST - 2 months ago

Invivyd Earnings Call Transcript: Q4 2025

2026-03-05T12:20:54.000Z - 2 months ago

Invivyd reports cash, cash equivalents of $226.7M as of December 31

2026-03-05T12:20:37.000Z - 2 months ago

Invivyd appoints Michael Mina as CMO

2026-03-05T12:13:36.000Z - 2 months ago

Invivyd reports FY25 EPS (30c) vs. ($1.43) last year

Mar 5, 2026, 7:03 AM EST - 2 months ago

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Mar 5, 2026, 7:01 AM EST - 2 months ago

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Mar 2, 2026, 4:10 PM EST - 2 months ago

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

2026-02-24T12:48:12.000Z - 2 months ago

Invivyd announces peer-reviewed publication using CANOPY trial data

Feb 24, 2026, 7:01 AM EST - 2 months ago

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

2026-02-18T17:40:26.000Z - 2 months ago

Invivyd management to meet virtually with BTIG

2026-02-03T12:05:43.000Z - 3 months ago

Invivyd aligns with FDA on LIBERTY Phase 3 trial of VYD2311

Feb 3, 2026, 7:01 AM EST - 3 months ago

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

2026-01-22T12:16:53.000Z - 3 months ago

Invivyd announces partnership with ski champion Lindsey Vonn

2026-01-20T12:11:41.000Z - 4 months ago

Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311

Jan 20, 2026, 7:01 AM EST - 4 months ago

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

2026-01-08T12:12:15.000Z - 4 months ago

Invivyd reports preliminary Q4 PEMGARDA net product revenue of $17.2M

Jan 8, 2026, 7:01 AM EST - 4 months ago

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

2025-12-23T12:10:26.000Z - 5 months ago

Invivyd earns Fast Track designation for VYD2311

2025-12-23T12:06:48.000Z - 5 months ago

Invivyd announces initiation of DECLARATION trial evaluating VYD2311

Dec 23, 2025, 7:05 AM EST - 5 months ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:01 AM EST - 5 months ago

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

2025-12-22T10:30:17.000Z - 5 months ago

Invivyd initiated with a Buy at BTIG

Dec 2, 2025, 2:35 PM EST - 5 months ago

Invivyd Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 7:01 AM EST - 6 months ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 7:01 AM EST - 6 months ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Nov 17, 2025, 10:40 PM EST - 6 months ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 17, 2025, 4:01 PM EST - 6 months ago

Invivyd Announces Proposed Public Offering of Common Stock

Nov 6, 2025, 8:30 AM EST - 6 months ago

Invivyd Earnings Call Transcript: Q3 2025

Nov 6, 2025, 7:01 AM EST - 6 months ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 3, 2025, 4:01 PM EST - 6 months ago

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Oct 30, 2025, 8:30 AM EDT - 6 months ago

Invivyd Transcript: Study Update

Oct 28, 2025, 7:01 AM EDT - 7 months ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 7 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Sep 24, 2025, 4:01 PM EDT - 8 months ago

Invivyd Appoints Paul B. Bolno, M.D.

Sep 17, 2025, 7:01 AM EDT - 8 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 8, 2025, 12:00 PM EDT - 8 months ago

Invivyd Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:01 AM EDT - 8 months ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Sep 3, 2025, 2:10 PM EDT - 8 months ago

Invivyd Transcript: Cantor Global Healthcare Conference 2025

Aug 27, 2025, 7:01 AM EDT - 9 months ago

Invivyd to Participate in Upcoming Investor Conferences

Aug 22, 2025, 12:00 PM EDT - 9 months ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 20, 2025, 11:58 PM EDT - 9 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 18, 2025, 4:32 PM EDT - 9 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 14, 2025, 4:49 PM EDT - 9 months ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:47 PM EDT - 9 months ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Jul 23, 2025, 7:01 AM EDT - 10 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 21, 2025, 7:05 AM EDT - 10 months ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 2, 2025, 7:01 AM EDT - 11 months ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jun 26, 2025, 7:01 AM EDT - 11 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

May 27, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 23, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 21, 2025, 9:30 AM EDT - 1 year ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 20, 2025, 11:00 AM EDT - 1 year ago

Invivyd Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Earnings Call Transcript: Q1 2025

May 15, 2025, 7:01 AM EDT - 1 year ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 7:01 AM EDT - 1 year ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 13, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 12, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 8, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Apr 21, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Mar 26, 2025, 4:15 PM EDT - 1 year ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 20, 2025, 8:01 AM EDT - 1 year ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 5, 2025, 7:05 AM EST - 1 year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Feb 24, 2025, 7:05 AM EST - 1 year ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 12, 2025, 1:20 PM EST - 1 year ago

Invivyd Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 10, 2025, 7:00 AM EST - 1 year ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Doom_Gloom_AR May. 12 at 11:45 PM

$IVVD still here

1 · Reply

trader2sde May. 11 at 11:40 PM

$IVVD https://nypost.com/2026/05/11/us-news/doj-weighing-new-criminal-case-against-dr-fauci-despite-bidens-autopen-pardon-and-statute-of-limitations/

0 · Reply

gb2017384 May. 11 at 3:32 PM

$IVVD ,IF THIS EVER GETS APPROVED,WHAT DOES EVERYONE THINK THE STOCK WILL PEAK AT THAT DAY ?,MY.GUESS WOULD BE BETWEEN $5 AND $7 A SHARE.

0 · Reply

trader2sde May. 11 at 12:32 PM

$IVVD news. !

0 · Reply

DARKP00L May. 11 at 11:20 AM

$IVVD 07:13 on May. 11 2026 Invivyd EVADE Trial Data Reveals Monoclonal Antibody VYD2311 Demonstrates Minimal Tolerability Issues Versus COVID mRNA Vaccination #tradeideas

0 · Reply

focafoca99 May. 11 at 11:18 AM

$IVVD rolled out a preprint comparing early tolerability of its low‑dose COVID monoclonal antibody to vaccine side effects.

0 · Reply

trader2sde May. 11 at 8:12 AM

0 · Reply

trader2sde May. 11 at 8:05 AM

$IVVD THIS IS SERIOUS. and major scandal in the making https://www.youtube.com/watch?v=j7fPU1Kp5mA

0 · Reply

trader2sde May. 11 at 1:13 AM

$IVVD why if everything if fine ?.... observe all info and think. it is that or sink the boat.

0 · Reply

trader2sde May. 10 at 9:07 PM

0 · Reply

trader2sde May. 10 at 8:46 PM

$IVVD hurry up guys,,, moderna with a bs vaccine PR doubled last 6months...

0 · Reply

trader2sde May. 10 at 5:06 AM

$IVVD well well well... Europe disagrees with incompetent CDC and weak WHO ( who had the guts to release all infected passengers back to their homes/States??). if this ANDES HANTA mutates with a European Hanta, buckle up ( there are bout 90 different Hanta viruses, brothers of ebola). up to 50 days incubation is also a .... problem ( like every thing is fine for 50 days so no quarantine needed lol). MODERNA is already a play even though their vaccine is YEARS away... will IVVD say something about mabs that so far are the only anti viral potential solution ? see post earlier.

0 · Reply

trader2sde May. 10 at 12:43 AM

$IVVD panic!! ( it is listed as side effects possible by pfizer itself lol)

0 · Reply

trader2sde May. 8 at 11:26 PM

$IVVD

0 · Reply

trader2sde May. 8 at 11:26 PM

$IVVD insane.... https://www.zerohedge.com/news/2026-05-08/who-inexplicably-immediately-releases-all-passengers-hantavirus-cruise-ship-without

0 · Reply

trader2sde May. 8 at 11:08 PM

$IVVD

0 · Reply

trader2sde May. 8 at 11:04 PM

$IVVD 1 MILLION schmucks arriving on East Coast in June for the world cup.... NOTHING TO WORRY ABOUT....

0 · Reply

trader2sde May. 8 at 7:50 PM

$IVVD

0 · Reply

trader2sde May. 8 at 1:33 PM

$IVVD lol what a joke. only mabs have a chance.

0 · Reply

trader2sde May. 8 at 11:01 AM

$IVVD https://www.npr.org/2026/05/07/nx-s1-5814761/hantavirus-likely-not-the-next-covid article says CDC is not reacting properly nor Argentina ( cases are doubling) and he IS concerned.... again so far ONLY specific mabs " can" be efficient against the hanta viruses.

0 · Reply

BioStick123 May. 7 at 7:25 PM

Biotech Buy of the Year - A year later today, the new buy of the year is $IVVD - we have a potential Phase 3 runup coming shortly and Phase 3 should be de-risked by its already-commercial COVID antibody infusion asset. IVVD has 200 million in cash with last round priced at $2.50 - now trading at $1.40 approaching the end of a catalyst-desert. Phase 3 readout for a <500M peak rev drug (COVID antibody for immunocomprised and elderly who do not respond well to vaccines), potentially much higher if efficacy for overall population is better than vaccines or if FDA makes a move against the vaccines. Readout in Q3'25. Long Covid Phase 2, vaccine comparitor trial and pipeline provide upside. $URGN $XBI

1 · Reply

trader2sde May. 7 at 12:51 PM

$IVVD current admin will try THEIR BEST to minimize this growing major crisis. just like dems did the opposite in 2019 . pay attention. up to IVVD to do their home work and use their AI programs to work on this as ONLY monoclonal specific antibodies can be efficient against hanta viruses ( no vaccine) Monoclonal antibodies (mAbs) against hantavirus are being developed as potential therapeutic treatments, as there are currently no FDA-approved vaccines or specific antivirals for the virus. Promising human mAbs, such as ANDV-44 and SNV-53, have demonstrated the ability to cross-neutralize both Old and New World hantaviruses and showed efficacy in animal models.

0 · Reply

Market Cap	427.03M
Revenue (ttm)	53.43M
Net Income (ttm)	-52.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-98.24%
Debt to Equity Ratio	0.00

Volume	1,028,800
Avg Vol	2,873,062
Day's Range	N/A - N/A
Shares Out	282.80M
Stochastic %K	59%
Beta	0.71
Analysts	Strong Sell
Price Target	$10.00